This clinical trial is focused on studying a condition called chronic non-infectious uveitis, which is an inflammation of the eye that is not caused by an infection. The treatment being tested in this study is a medication called adalimumab, which is commonly used to reduce inflammation in various conditions. Adalimumab will be administered as a solution for injection, either in a pre-filled syringe or a pre-filled pen.

The purpose of the study is to evaluate a new strategy for using adalimumab in patients with chronic non-infectious uveitis who have already achieved a complete response to treatment. The study will compare a new approach, which involves adjusting the timing of adalimumab doses based on monitoring drug levels in the body, to the usual way of giving the medication. The goal is to see if this new approach can maintain the patients’ eye health and prevent infections over a period of 48 weeks.

Participants in the study will receive adalimumab injections and will be monitored regularly to assess their eye health and check for any signs of infection. The study will also look at the quality of life of participants and the cost-effectiveness of the treatment. This trial aims to provide valuable information on whether adjusting the dosing schedule of adalimumab based on drug levels can offer better outcomes for patients with chronic non-infectious uveitis.